COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,681 Articles (22,913 medRxiv, 8,768 bioRxiv)

Most recent first Previous |  Page 1090: Articles 10891-10900  | Next

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants
Zhang, L., Dutta, S., Xiong, S., Chan, M., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M., Cooper, L. M., Rong, L., Gugliuzza, A. F., Shukla, D., Procko, E., Rehman, J., Malik, A. B.
10.1101/2021.12.21.473668 — Posted: 2021-12-22
An in silico analysis of early SARS-CoV-2 variant B.1.1.529 (Omicron) genomic sequences and their epidemiological correlates
Kumar, A., Asghar, A., Singh, H. N., Faiq, M. A., Kumar, S., Narayan, R. K., Kumar, G., Dwivedi, P., Sahni, C., Jha, R. K., Kulandhasamy, M., Prasoon, P., Sesham, K., Kant, K., Pandey, S. N.
10.1101/2021.12.18.21267908 — Posted: 2021-12-22
Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant
Bekliz, M., Adea, K., Alvarez, C., Essaidi-Laziosi, M., Escadafal, C., Kaiser, L., Eckerle, I.
10.1101/2021.12.18.21268018 — Posted: 2021-12-22 Discussion: Onsite | Offsite
Structural flexibility of the SARS-CoV-2 genome relevant to variation, replication, pathogenicity, and immune evasion.
Patarca, R., Haseltine, W. A.
10.1101/2021.12.20.473542 — Posted: 2021-12-21
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
Hansen, C. H., Schelde, A. B., Moustsen-Helms, I. R., Emborg, H.-D., Krause, T. G., Moelbak, K., Valentiner-Branth, P., The Infectious Disease Preparedness Group at Statens Serum Institut
10.1101/2021.12.20.21267966 — Posted: 2021-12-21 Discussion: Onsite
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R., Moyo, S., Amoako, D. G., Tegally, H., Scheepers, C., Lessells, R. J., Giandhari, J., Wolter, N., Everatt, J., Rambaut, A., Althaus, C., Wilkinson, E., Mendes, A., Strydom, A., Davids, M., Mayaphi, S., Gaseitsiwe, S., Choga, W. T., Maruapula, D., Zuze, B., Radibe, B., Koopile, L., Shapiro, R., Lockman, S., Mbulawa, M. B., Mphoyakgosi, T., Smith-Lawrence, P., Mosepele, M., Matshaba, M., Masupu, K., Chand, M., Joseph, C., Kuate-Lere, L., Lesetedi-Mafoko, O., Moruisi, K., Scott, L., Stevens, W., Wibmer, C. K., Mnguni, A., Ismail, A., Mahlangu, B., Martin, D. P., Hill, V., Colquhoun, R.
10.1101/2021.12.19.21268028 — Posted: 2021-12-21
GB0139, an inhaled small molecule inhibitor of galectin-3, in COVID-19 pneumonitis: a randomised, controlled, open-label, phase 2a experimental medicine trial of the safety, pharmacokinetics, and potential therapeutic value
Gaughan, E., Sethi, T., Quinn, T., Hirani, N., Mills, A., Bruce, A. M., MacKinnon, A., Aslanis, V., Li, F., O'Connor, R., Parker, R. A., Norrie, J., Dear, J., Akram, A. R., Koch, O., Wang-Jairaj, J., Slack, R. J., Gravelle, L., Lindmark, B., Dhaliwal, K.
10.1101/2021.12.21.21267983 — Posted: 2021-12-21
Spatiotemporal patterns and progression of the Delta variant of COVID-19 and their health intervention linkages in Southeast Asia
Luo, W., Liu, Z., Zhou, Y., Zhao, Y., Li, Y. E., Masrur, A., Yu, M.
10.1101/2021.12.20.21268140 — Posted: 2021-12-21
Immunity acquired by a minority active fraction of the population could explain COVID-19 spread in Greater Buenos Aires (June-November 2020)
Fabricius, G., Borzi, R., Caminos, J., Grigera, T. S.
10.1101/2021.12.21.21267955 — Posted: 2021-12-21
Statistical Forecasting : Third Wave of COVID-19-With an Application to India
Rajeshbhai, S. P., Dhar, S. S., Shalabh, S.
10.1101/2021.12.20.21268150 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).